Table 3 Treatment data during hospitalization of COVID-19 patients
Treatment Data | Diabetes group | Non-diabetes group | Diabetes group | Non-diabetes group | OR | CI | P value | Critical P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Variables (N = 28) | median | IQR | median | IQR | (%) | Positive/total | (%) | Positive/total | ||||
Antiplatelet, % | 28.98 | 353/1218 | 13.33 | 281/2108 | 2.653 | 2.224–3.165 | < 0.0001 | 0.00179 | ||||
RAASi, % | 34.32 | 418/1218 | 22.66 | 478/2109 | 1.783 | 1.525–2084 | < 0.0001 | 0.00185 | ||||
Vasoactive drug, % | 60.25 | 676/1122 | 49.36 | 925/1874 | 1.555 | 1.338–1.807 | < 0.0001 | 0.00192 | ||||
Oxygen therapy, % | 94.37 | 1139/1207 | 88.93 | 1847/2077 | 2.086 | 1.576–2.761 | < 0.0001 | 0.00200 | ||||
Intensive care unit, % | 69.95 | 852/1218 | 60.36 | 1273/2109 | 1.529 | 1.315–1.777 | < 0.0001 | 0.00208 | ||||
Intubation, % | 59.49 | 677/1138 | 50.45 | 960/1903 | 1.443 | 1.243–1.674 | < 0.0001 | 0.00217 | ||||
Dialysis, % | 24.79 | 302/1218 | 19.25 | 406/2109 | 1.383 | 1.168–1.638 | 0.0002 | 0.00227 | ||||
Anticoagulant drug, % | 98.11 | 1195/1218 | 95.78 | 2020/2109 | 2.289 | 1.439–3.641 | 0.0005 | 0.00238 | ||||
Hospital stay (days) | 12.00 | 7–20 | 11.00 | 6–19 | 0.0274 | 0.00250 | ||||||
Anticoaguant drug duration (days) | 10.97 | 5.79–19.24 | 10.13 | 5.31–18.39 | 0.0549 | 0.00263 | ||||||
Antiviral drug, % | 32.35 | 394/1218 | 35.63 | 751/2108 | 0.8640 | 0.7440–1.003 | 0.0552 | 0.00278 | ||||
Antifungal drug n = 269, % | 9.28 | 113/1218 | 7.40 | 156/2108 | 1.280 | 0.9934–1.648 | 0.0648 | 0.00294 | ||||
Dialysis duration (days) | 6.00 | 2–13 | 7.00 | 2–16 | 0.0912 | 0.00313 | ||||||
Antibiotic drug duration (days) | 5.42 | 2.63–13.27 | 5.20 | 2.39–12.53 | 0.1344 | 0.00333 | ||||||
RAASi drug duration | 5.38 | 2.10–10.02 | 4.96 | 1.86–9.73 | 0.1819 | 0.00357 | ||||||
Antiviral drug duration (days) | 1.71 | 0.50–3.62 | 1.84 | 0.50–3.68 | 0.2249 | 0.00385 | ||||||
Immunossuppressordrug, % | 3.94 | 48/1218 | 3.23 | 68/2108 | 1 | 0.8446- 1.793 | 0.3247 | 0.00417 | ||||
Antibiotic drug, % | 92.36 | 1125/1218 | 91.46 | 1928/2108 | 1.129 | 0.8700–1.466 | 0.3959 | 0.00455 | ||||
Immunosuppressor duration (days) | 5.74 | 2.62–13.06 | 5.95 | 2.47–14.41 | 0.4272 | 0.00500 | ||||||
Antiplatelet drug duration (days) | 7.42 | 3.45–13.78 | 6.29 | 2.20–12.89 | 0.4691 | 0.00556 | ||||||
Endotraqueal entubation duration (days) | 10.00 | 6.0–17 | 10.00 | 6.0–16 | 0.5349 | 0.00625 | ||||||
Glicocorticoid drug, % | 62.07 | 756/1218 | 60.96 | 1285/2108 | 1.048 | 0.9065–1.212 | 0.5506 | 0.00714 | ||||
Intensive Care Unit stay (days) | 10.00 | 5–17 | 9.00 | 5–17 | 0.5872 | 0.00833 | ||||||
Vasoactive drug duration (days) | 6.00 | 3–11 | 6.00 | 3–10 | 0.6657 | 0.01000 | ||||||
Antifungal drug duration (days) | 3.76 | 1.00–6.62 | 5.40 | 1.32–9.72 | 0.9289 | 0.01250 | ||||||
Tracheostomy, % | 12.59 | 85/675 | 12.43 | 119/957 | 1.015 | 0.7533–1.366 | 0.9395 | 0.01667 | ||||
Glicocorticoid drug duration (days) | 6.95 | 3.08–14.08 | 6.88 | 3.03–13.99 | 0.9917 | 0.02500 | ||||||
Blood transfusion, % | 19.70 | 240/1218 | 19.63 | 414/2109 | 1.005 | 0.8413–1.200 | 0.9947 | 0.05000 | ||||